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Abstract
The currently available antihypertensive agents have undesirable
adverse effects due to systemically altering target activity includ-
ing receptors, channels, and enzymes. These effects, such as loss
of potassium ions induced by diuretics, bronchospasm by beta-
blockers, constipation by Ca2+ channel blockers, and dry cough by
ACEI, lead to non-compliance with therapies (Moser, 1990). Here,
based on new hypertension mechanisms, we explored a new anti-
hypertensive approach. We report that transient receptor poten-
tial vanilloid 4 (TRPV4) interacts with Ca2+-activated potassium
channel 3 (KCa2.3) in endothelial cells (ECs) from small resistance
arteries of normotensive humans, while ECs from hypertensive
patients show a reduced interaction between TRPV4 and KCa2.3.
Murine hypertension models, induced by high-salt diet, N(G)-
nitro-L-arginine intake, or angiotensin II delivery, showed
decreased TRPV4-KCa2.3 interaction in ECs. Perturbation of the
TRPV4-KCa2.3 interaction in mouse ECs by overexpressing full-
length KCa2.3 or defective KCa2.3 had hypotensive or hyperten-
sive effects, respectively. Next, we developed a small-molecule
drug, JNc-440, which showed affinity for both TRPV4 and KCa2.3.
JNc-440 significantly strengthened the TRPV4-KCa2.3 interaction
in ECs, enhanced vasodilation, and exerted antihypertensive
effects in mice. Importantly, JNc-440 specifically targeted the
impaired TRPV4-KCa2.3 interaction in ECs but did not systemically
activate TRPV4 and KCa2.3. Together, our data highlight the
importance of impaired endothelial TRPV4-KCa2.3 coupling in the
progression of hypertension and suggest a novel approach for
antihypertensive drug development.
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Introduction
Currently available antihypertensive drugs, which include diuretics,
beta-blockers, angiotensin-converting enzyme inhibitors, angio-
tensin receptor blockers, and Ca2+ channel blockers, exert effects
on cardiac output or sympathetic neural activity, resulting in
reduced blood pressure. In addition to these pathogenic mechanisms
of disease, which are targeted by existing antihypertensive drugs,
changes in the vascular resistance of small resistance arteries have
been implicated in the development of hypertension (Moser, 1990;
Panza et al, 1990; Wong et al, 2004). Notably, however, the critical
role of endothelial cells (ECs) in small resistance arteries in the
pathogenesis of hypertension has been largely ignored to date.
In hypertension, functional changes in small resistance arteries are
frequently accompanied by abnormalities of the ECs in these vessels
(Feletou & Vanhoutte, 2006a). While endothelium-dependent relax-
ation is selectively mediated by nitric oxide in the large conduit
vessels, endothelium-derived hyperpolarizing factor (EDHF) is the
predominant vasodilator in small resistance arteries (Brandes et al,
2000; Busse et al, 2002). An absence of EDHF increases peripheral
resistance and blood pressure (Panza et al, 1990; Feletou et al, 2010);
in turn, the endothelial dysfunction is reinforced, and then compli-
ance and pressure reflectivity in the arteries are attenuated, which
further increases blood pressure, thereby causing a vicious cycle
(Laurent et al, 2006; Najjar et al, 2008). Therefore, targeting the func-
tion of small arteries via the EDHF signaling pathway tends to be an
effective means of treating hypertension (Feletou & Vanhoutte, 2009).
Endothelial K+ channels, including the small conductance and
intermediate conductance Ca2+-activated K+ channels, contribute
significantly to the EDHF response (Burnham et al, 2002; Bychkov
et al, 2002; Garland et al, 2011; Sonkusare et al, 2012), and the
presence of TRPV4 is essential for this response (Watanabe et al,
2003; Vriens et al, 2005; Earley et al, 2009; Bagher et al, 2012). We
previously demonstrated that physical and functional interaction of
TRPV4 with the Ca2+-activated K+ channel KCa2.3 is responsible
for the EDHF response in ECs (Ma et al, 2013). This type of channel
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association allows Ca2+ entry through TRPV4 channels to stimulate
neighboring KCa2.3 channels in subcellular microdomains, evoking
the EDHF response and contributing to the subsequent vascular
relaxation and regulation of blood flow and blood pressure. Here,
with the goal of effectively treating hypertension and cutting down
on the accompanying adverse effects due to systemic activation, we
explored the mechanism by which hypertension is caused by
dysregulated TRPV4-KCa2.3 interaction; we also identified a poten-
tially therapeutic small molecule like a pin targeting impaired
endothelial TRPV4-KCa2.3 interaction (Fig 1A).
Results and Discussion
Impairment of the physical and functional interaction of
TRPV4-KCa2.3 channels in hypertension
To examine the role of TRPV4-KCa2.3 interaction in hypertension,
we assessed the interaction between these two proteins in ECs from
human arterial segments using Fo¨rster resonance energy transfer
(FRET) (Adebiyi et al, 2010, 2012) and found that the physical inter-
action between TRPV4-KCa2.3 was lower in cells from hypertensive
patients than in those from normotensive individuals (Fig 1B,
Appendix Fig S1A and B, and Appendix Table S1). Next, we treated
mice with a high-salt diet, N(G)-nitro-L-arginine (L-NNA) intake, or
angiotensin II (AngII) delivery to generate murine hypertension
models, and the FRET results showed that TRPV4-KCa2.3 interac-
tion was similarly reduced in the hypertensive and control mice
(Fig 1C–E). The TRPV4-KCa2.3 interaction in mouse ECs was also
confirmed by co-immunoprecipitation (co-IP) (Appendix Fig S2A),
which also showed that the interaction was decreased in hyperten-
sive mice (Appendix Fig S2B).
We previously showed that the function of KCa2.3 is dependent
on TRPV4 and is responsible for the EDHF response in ECs (Ma
et al, 2013). Here, we further explored whether destruction of physi-
cal TRPV4-KCa2.3 interaction abolished their functional interaction.
In mouse primary arterial ECs, the specific TRPV4 agonist
GSK1016790A dose-dependently induced K+ efflux (Fig 1F), indicat-
ing the functional interaction of TRPV4 with KCa2.3. Consistently,
whole-cell patch clamp recordings from primarily cultured ECs
showed that GSK1016790A induced a whole-cell current, which was
inhibited by the TRPV4 inhibitor HC067047, but not by the KCa2.3
inhibitor apamin (Appendix Fig S3A). In contrast, the KCa2.3 activa-
tor CyPPA induced a whole-cell current, which was inhibited by the
TRPV4 inhibitor HC067047 (Appendix Fig S3B), suggesting again
the functional interaction of TRPV4-KCa2.3 and the dependence of
KCa2.3 function on TRPV4. We then showed that the functional
interaction of TRPV4 and KCa2.3 including K+ efflux in ECs (Fig 1F)
and the dilation in freshly isolated arterial segments induced by
GSK1016790A was decreased in mice that had been fed a high-salt
diet (Fig 1G). These data suggest that the interrupted physical
TRPV4-KCa2.3 interaction consequently impaired the functional
TRPV4-KCa2.3 interaction.
To clarify the involvement of EDHF in this TRPV4-KCa2.3 mech-
anism in hypertension, we showed in freshly isolated small arterial
segments from mice on a high-salt diet, acetylcholine (ACh)-induced
vasodilation was weakened, but sodium nitroprusside (SNP)-
induced vasodilation was not significantly changed (Fig 1G). These
results are consistent with previous reports (Barron et al, 2001)
and suggest that a high-salt diet weakens EDHF-dependent, but
not nitric oxide-dependent vasodilation. Consistently, by measuring
membrane potentials via sharp microelectrodes inserted from the
adventitial side in small arteries, we showed that the smooth muscle
hyperpolarization, which is an indicator of EDHF release (Busse
et al, 2002; Feletou & Vanhoutte, 2006b, 2009), was activated by
GSK1016790A or ACh. An antagonist of KCa2.3 (apamin) or TRPV4
(HC067047) inhibited ~80% of the hyperpolarization induced by
GSK1016790A or ACh (Appendix Fig S4). Thus, these data suggest
that EDHF is the dominant component here and that TRPV4-KCa2.3
contributes to such EDHF signaling.
We further attempted to identify the domains/regions involved
in TRPV4-KCa2.3 interaction using deletion assays and FRET in
▸Figure 1. Impairment of the physical and functional interaction of TRPV4-KCa2.3 channels in hypertension.A The hypothesis investigated in this study was that endothelial TRPV4-KCa2.3 interaction modulates blood pressure, and impairment of the interaction is related to
hypertension. So, strengthening the interaction with a small-molecule drug, JNc-440, would show antihypertensive effects.
B Immuno-FRET experiments in arterial sections from normotensive and hypertensive humans. Left: representative figures for FRET. White dotted line,
autofluorescence of elastin underneath the endothelium; right: analysis of 21 normotensive and 15 hypertensive individuals (#P < 0.0001, unpaired t-test vs.
control). Scale bar, 20 lm.
C–E Immuno-FRET experiments in arterial sections from (C) mice on a high-salt diet (8% NaCl), (D) mice with L-NNA intake (0.5 g/l in the drinking water), or (E) mice
with AngII delivery (infused at 500 ng/kg/min) (#P < 0.0001, unpaired t-test vs. control).
F Fluorescent K+ efflux results showing the TRPV4 agonist GSK1016790A (GSK)-induced K+ efflux in primary cultured ECs from normal mice and mice on a high-salt
diet (left). Six mice were tested for each treatment and analyzed (right). ECs from TRPV4-knockout (KO) mice were used as negative controls [#P < 0.0001, two-way
ANOVA (GSK 30 nM, high salt vs. control; GSK 100 nM, high salt vs. control)].
G Modulation of vasodilation by GSK1016790A (GSK), acetylcholine (ACh), and sodium nitroprusside (SNP). Left: vasodilation assays by wire myograph showing
GSK1016790A (GSK)-induced dilation in freshly isolated arterial segments from normal mice and mice on a high-salt diet. Second from left: five mice were
tested for each treatment and statistically analyzed (#P < 0.0001 vs. control, two-way ANOVA). Rightmost two panels: statistical data of vasodilation for ACh
(n = 3/treatment) and SNP (n = 3/treatment) treatment in freshly isolated arterial segments from normal mice and mice on a high-salt diet (*P < 0.0001,
#P = 0.0004 vs. control, two-way ANOVA).
H FRET in HEK cells co-expressing CFP-tagged TRPV4 and YFP-tagged KCa2.3 showing the critical role of the AR2 and C-terminal 17-amino acid (17C) regions in the
interaction. TRPV4 was deleted at the different AR and CaMBD regions, whereas KCa2.3 was deleted at the 17C, a1, a2, Loop, and CAMBD regions. NC, negative
control, assessed in cells co-expressing CFP and YFP as separate molecules; PC, positive control, assessed in cells expressing YFP-CFP dimer (#P < 0.0001 vs. wild-
type control (TRPV4-KCa2.3), one-way ANOVA).
I Stochastic optical reconstruction images of the indicated constructs in overexpressing HEK cells (scale bars, 10 lm).
Data information: Data are given as the mean  SD.
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HEK cells co-expressing CFP-tagged TRPV4 and YFP-tagged KCa2.3.
The N-terminal ankyrin repeat domain (AR) of TRPV4 and the CaM-
binding domain (CaMBD) of KCa2.3 are known to be critical for
their function (Schumacher et al, 2001; Strotmann et al, 2003;
Cifuentes et al, 2004; Stocker, 2004; Roncarati et al, 2005; Zhu,
2005; Phelps et al, 2010; Takahashi et al, 2014). Deletion of either
the AR2 cytoplasmic region of TRPV4 (ΔAR2) or a 17-amino acid
region in the C-terminal cytoplasmic region of KCa2.3 (Δ17C), but
not of various other regions within these two channels, significantly
decreased the FRET signal, indicating that these regions are respon-
sible for the interaction (Fig 1H). Mutation of either protein had no
evident effect on channel function or cellular localization
(Appendix Figs S5 and S6). The critical role of the TRPV4-AR2 and
the KCa2.3-17C regions in the interaction was confirmed by stochas-
tic optical reconstruction microscopy (Fig 1I). Together, these
results indicated that in the setting of hypertension, physical and
functional interaction of TRPV4 and KCa2.3 in ECs is reduced, and
the TRPV4-AR2 and KCa2.3-17C regions are critical for this
interaction (Fig 1).
We then investigated the mechanism by which TRPV4 and
KCa2.3 become disassociated in hypertension. Caveolin-1 is the
major structural protein of caveolae, and acts as a scaffold for
clusters of ion channels and signaling molecules within them.
Within the caveolin-1 scaffold of EC caveolae, the Ca2+-dependent
effector KCa2.3 resides within the spatial boundaries of the Ca2+-
permeable TRPV4 channels. This subcellular arrangement may
enhance the ability of KCa2.3 to sense Ca2+ influx through TRPV4
channels (Loot et al, 2008; Saliez et al, 2008; Goedicke-Fritz et al,
2015). In the setting of hypertension, the caveolin-1 scaffold is
disrupted (Mathew et al, 2004; Zhang et al, 2014b), and we
hypothesized that this disruption is accompanied by physical sepa-
ration of TRPV4 and KCa2.3. To test this, we first confirmed that
caveolin-1 associated with TRPV4 and KCa2.3 and that TRPV4 and
KCa2.3 associated with each other in the caveolae of murine ECs
under normal conditions (Appendix Figs S2A and S7). Next, we
treated mice with high-salt diet, L-NNA intake, or AngII delivery,
and found that the TRPV4-KCa2.3 interaction localization with
caveolin-1 in ECs decreased (Appendix Fig S7). Furthermore,
exposure to methyl b-cyclodextrin, an agent known to disrupt
caveolae and caveolae-dependent signaling (Lohn et al, 2000;
Dedkova et al, 2003), decreased the TRPV4-KCa2.3 interaction and
GSK1016790A-induced K+ efflux in primary ECs (Appendix Fig
S8A and B), as well as GSK1016790A- or ACh-induced vasodilation
in freshly isolated arterial segments (Appendix Fig S8C). Consis-
tently, knockdown of caveolin-1 in ECs by adeno-associated virus
(AAV) siRNA (AAV-siRNA-caveolin-1) (Morishita et al, 1995)
decreased the TRPV4-KCa2.3 interaction and GSK1016790A-
induced K+ efflux in primary ECs, as well as GSK1016790A- or
ACh-induced vasodilation in freshly isolated arterial segments
(Appendix Fig S8D). These results suggest that TRPV4 and KCa2.3
cluster in specific positions within the cell membrane to form func-
tional units and that caveolae may constitute the scaffolding for
this micro-compartmental organization.
Increasing the TRPV4-KCa2.3 interaction lowers blood pressure,
but dissociation of TRPV4-KCa2.3 interaction increases
blood pressure
To investigate the role of TRPV4-KCa2.3 interaction in the regula-
tion of blood pressure in vivo, a KCa2.3-expressing AAV vector
(AAV-Flt1-KCa2.3) was used to increase the interaction in the ECs
of normotensive mice. Intravenously injected AAV-Flt1-KCa2.3
effectively infected the endothelium (Fig 2A) and significantly
increased the degree of TRPV4-KCa2.3 co-localization in vivo
(Fig 2B). Functionally, AAV-Flt1-KCa2.3 enhanced the
GSK1016790A-induced K+ efflux from primary ECs (Fig 2C), as well
as GSK1016790A-induced or ACh-induced vasodilation in freshly
isolated arterial segments (Fig 2D). As a result, AAV-Flt1-KCa2.3
significantly lowered the mean arterial pressure of normotensive
mice (Fig 2E). Notably, AAV-Flt1-KCa2.3-enhanced K+ efflux and
vasodilation, along with the hypotensive effect of AAV-Flt1-KCa2.3,
were absent from TRPV4-knockout mice (Fig 2F–H), suggesting that
the functional interaction of TRPV4 and KCa2.3 depends on TRPV4
in order to modulate blood pressure.
We then generated an AAV vector that expressed the 17 amino
acids in the C-terminal of KCa2.3 in ECs only, AAV-Flt1-KCa2.3-
17C, to reduce TRPV4-KCa2.3 interaction in normotensive mice. In
contrast to the findings with AAV-Flt1-KCa2.3, tail injection of AAV-
Flt1-KCa2.3-17C into normotensive mice significantly decreased the
degree of TRPV4-KCa2.3 interaction in vivo (Fig 2I). It also reduced
the GSK1016790A-induced K+ efflux from primary ECs (Fig 2J), as
well as GSK1016790A-induced or ACh-induced vasodilation in
freshly isolated arterial segments (Fig 2K). As a result, AAV-Flt1-
KCa2.3-17C increased the mean arterial pressure (Fig 2L). Notably,
these effects of AAV-Flt1-KCa2.3-17C were abolished in the absence
of TRPV4 (Fig 2M–O).
▸Figure 2. Increasing the TRPV4-KCa2.3 interaction lowers blood pressure, but dissociation of TRPV4-KCa2.3 interaction increases blood pressure.A–H Mice were intravenously injected with AAV-Flt1-KCa2.3 and the AAV-Flt1 vector served as a control. (A) Representative en face (left) and cross-sectional (right)
fluorescence images of AAV-Flt1-KCa2.3 or vector (flag-tag) expression in AAV-Flt1-infected mice. Green, autofluorescence of elastin underneath the endothelium
(excitation, 488 nm); red, anti-flag. Scale bars, 10 lm. (B) Seven mice were tested for the effects of AAV-Flt1-KCa2.3 or vector in immuno-FRET experiments
(#P < 0.0001 vs. control, unpaired t-test). (C, F) K+ efflux from primary cultured ECs (#P < 0.0001 vs. control, unpaired t-test). (D, G) Vasodilation assays by wire
myography (GSK1016790A (GSK) and ACh in freshly isolated arterial segments) (*P = 0.047, #P < 0.0001 vs. control, two-way ANOVA). (E, H) Time course of the
changes in mean arterial pressure (ΔMAP) in wild-type (C–E) and TRPV4-knockout (KO) (F–H) mice after tail injection of AAV-Flt1-KCa2.3, AAV-Flt1 vector, or vehicle
(injection solution).
I–O Mice were intravenously injected with AAV-Flt1-KCa2.3-17C; the AAV-Flt1 vector served as the control. (I) Mice were tested for effects of AAV-Flt1-KCa2.3-17C or
vector with immuno-FRET experiments (#P < 0.0001 vs. control, unpaired t-test). (J, M) K+ efflux from primary cultured ECs (#P < 0.0001 vs. control, unpaired
t-test). (K, N) Vasodilation assays by wire myography (GSK1016790A (GSK) and ACh) in freshly isolated arterial segments) (*P = 0.004, #P < 0.0001 vs. control,
two-way ANOVA). (L, O) Time course of the changes in mean arterial pressure (ΔMAP) in wild-type (J–L) and TRPV4-knockout (KO) (M–O) mice after tail injection of
AAV-Flt1-KCa2.3-17C, AAV-Flt1 vector, or vehicle (injection solution).
Data information: Data are mean  SD.
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Increasing the TRPV4-KCa2.3 interaction with JNc-440
is antihypertensive
The results shown in Fig 2 indicate that manipulating the TRPV4-
KCa2.3 interaction is effective in modulating arterial function and
blood pressure. We therefore set out to develop a molecule to attach
the AR2 region of TRPV4 onto the 17C region of KCa2.3 in ECs to
restore the TRPV4-KCa2.3 dissociation found under hypertensive
conditions (see strategy in Fig 1A). Based on an analysis of the
molecular docking between the 3D structures of TRPV4 and KCa2.3,
we screened and synthesized a series of chemical compounds.
Among these, JNc-440 (C26H24N4O3,N-(3-(2,2-diphenylacetamido)
propyl)-4-oxo-1,4-dihydroquinazoline-2-carboxamide) was a potent
enhancer of TRPV4-KCa2.3 interaction because it showed high affin-
ity for both TRPV4 and KCa2.3 (Fig 3A and Appendix Fig S9). In the
setting of a high-salt diet, JNc-440 had a protective effect on TRPV4-
KCa2.3 interaction in vitro at 10 lM (Appendix Fig S10A). Next,
JNc-440 was injected into the tails of mice treated with a high-salt
diet, L-NNA intake, or AngII delivery to further assess its protective
effect on the physical and functional interaction of TRPV4-KCa2.3
and blood pressure. After injection, JNc-440 circulated in the blood
(Appendix Fig S10B) and showed a clear distribution throughout the
ECs 15 min after injection (Appendix Fig S10C), as well as signifi-
cantly augmenting the degree of TRPV4-KCa2.3 interaction in the
three types of hypertensive mice (Fig 3B). This occurred as early as
2 h after injection at 1 mg/kg (Appendix Fig S10D). Treatment with
JNc-440 also enhanced the GSK1016790A-induced K+ efflux in ECs
(Fig 3C) and increased GSK1016790A- or ACh-induced vasodilation
in freshly isolated arterial segments (Fig 3D) from hypertensive
mice. Further, JNc-440 had significant antihypertensive effects
(Appendix Fig S10E; Fig 3E, daily for 1 week). Importantly, the anti-
hypertensive effect was absent in normotensive mice (Fig 3F and
Appendix Fig S10F). Further, these effects depended on the presence
of TRPV4, as JNc-440 was ineffective in TRPV4-knockout mice
(Fig 3G). These findings suggest that JNc-440 increases the impaired
TRPV4-KCa2.3 interaction to improve endothelium-dependent relax-
ation in small resistance arteries and to lower blood pressure.
Endothelial TRPV4 and KCa2.3 are effective targets for modulat-
ing blood pressure (Taylor et al, 2003; Brahler et al, 2009; Earley
et al, 2009; Gao & Wang, 2010). As TRPV4 and KCa2.3 are both
widely expressed and participate in important physiological func-
tions, drugs that cause their systemic activation often have severe
adverse effects, including endothelial failure and circulatory collapse
(Willette et al, 2008). We therefore assessed TRPV4 and KCa2.3
activity in normotensive mice treated with JNc-440 and found that
JNc-440 did not alter the activity of either TRPV4 or KCa2.3
(Appendix Fig S11A and B). As a result, JNc-440 did not change the
blood pressure in normotensive mice. Thus, we conclude that by
strengthening impaired endothelial TRPV4-KCa2.3 interaction, JNc-
440 might be a useful antihypertensive treatment without adverse
systemic effects.
In summary, we have shown that TRPV4-KCa2.3 interaction in
ECs is essential to modulate blood pressure, and JNc-440 can protect
this interaction and treat hypertension. Our data highlight the
importance of impaired TRPV4-KCa2.3 interaction in the progress of
hypertension and provide a novel strategy of developing new anti-
hypertensive drugs with fewer adverse effects.
Materials and Methods
Human artery specimens
The use of human arteries was approved by the Review Board at the
Affiliated Hospital, Jiangnan University, and the experiments
conformed to the principles set out in the WMA Declaration of
Helsinki and the Department of Health and Human Services
Belmont Report. All patients provided written informed consent for
the collection of samples. Mesenteric, femoral, popliteal, and
brachial arteries were harvested from surgical specimens from
normotensive and hypertensive patients. The mean age of patients
was 51.3 years (range, 41–62 years). A history of hypertension was
defined as having persistent elevated blood pressure, systolic pres-
sure > 140 mmHg, or diastolic pressure > 90 mmHg and requiring
medical treatment. The background information on patients is
presented in Appendix Table S1.
Animals
All animal experiments were performed in accordance with the
laboratory animal guidelines and with the approval of the Animal
Experimentations Ethics Committee, Jiangnan University. TRPV4-
knockout (TRPV4/) (Suzuki et al, 2003) mice were from Dr.
Makoto Suzuki (Jichi Medical School, Tochigi, Japan and RIKEN
BioResource Center, Japan). TRPV4/ and wild-type C57BL/6J
mice at 2–4 months of age were used. In some experiments, mice
were made hypertensive by (i) addition of the NOS inhibitor Nx-
nitro-L-arginine (L-NNA) to the drinking water (0.5 g/l; 7-day dura-
tion) (Earley et al, 2009; Gonzalez-Villalobos et al, 2013); (ii) deliv-
ery of AngII at an infusion rate of 500 ng/kg/min for 14 days by
osmotic pump (Model 2004, Azlet); or (iii) provision of a high-salt
diet (8% NaCl) for 3 weeks (Wang et al, 2012; Chen et al, 2015). A
normal-salt diet (0.3% NaCl) diet served as control. Systolic and
diastolic blood pressure was recorded by tail-cuff plethysmography
◀ Figure 3. Increasing the TRPV4-KCa2.3 interaction with JNc-440 is antihypertensive.A Left: structural formula of JNc-440. Right: affinity of JNc-440 for both TRPV4 and KCa2.3. Biotinylated JNc-440 (JNc-440-biotin) pulled down TRPV4 or KCa2.3 in
primary cultured ECs.
B–G (B) Immuno-FRET experiments in arterial sections, (C) K+ efflux from primary cultured ECs, (D) vasodilation assays by wire myography (GSK and ACh) in freshly
isolated arterial segments, and (E) mean arterial pressure. (F) Effect of JNc-440 on blood pressure in normotensive mice. (G) Effect of JNc-440 (1 mg/kg; daily for
1 week) on blood pressure in TRPV4-knockout (KO) mice treated with a high-salt diet, L-NNA, or AngII. WT mice were treated with a high-salt diet, L-NNA, or AngII
and then intravenously injected with JNc-440 (1 mg/kg) or vehicle for 2 h (B–F) or daily for 1 week (G). Data are mean  SD. (B, C) #P < 0.0001 vs. control,
unpaired t-test. (D) *P = 0.025 (high-salt diet), *P = 0.008 (L-NNA treatment), or *P = 0.021 (AngII treatment), #P < 0.0001 vs. control, two-way ANOVA. (E)
*P = 0.001, #P < 0.0001 vs. control, two-way ANOVA.
Source data are available online for this figure.
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(NIPB-2 blood pressure monitor, Columbus Instruments), and the
mean arterial pressure was calculated from these data as previously
reported (Taylor et al, 2003; Gonzalez-Villalobos et al, 2013). The
average of three to four measurements on each day of treatment
was taken to be the representative pressure for each animal.
Cell preparation and culture
Primary mesenteric artery endothelial cells were isolated from
C57BL/6 mice and used for experiments without passage. Briefly,
after anesthesia, the abdomen was opened, the small intestines
were dissected out, and the mesenteric bed containing blood
vessels along the small intestines was carefully removed. The
remaining arterial branches were digested with 0.02% collagenase
in endothelium basal medium for 45 min at 37°C. After centrifuga-
tion at 845 g for 5 min, the pelleted cells were re-suspended in
endothelial complete medium (ECM) supplemented with 5% fetal
bovine serum (FBS) and 1% endothelial cell growth supplement
and cultured in a flask at 37°C with 5% CO2. Non-adherent cells
were removed 2 h later. The adherent endothelial cells were
cultured with ECM at 37°C with 5% CO2 for 1–2 days (Ma et al,
2013). HEK293 cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% FBS, 100 lg/ml penicillin, and
100 U/ml streptomycin.
Immunostaining and immunofluorescence resonance
energy transfer
Immuno-FRET was measured as previously described (Adebiyi et al,
2010). Tissue slides were de-paraffinized with 4% paraformalde-
hyde, washed with PBS, and incubated for 1 h with 10% bovine
serum albumin and 1% Triton X-100 in PBS. The slides were incu-
bated with the primary antibody [goat monoclonal anti-TRPV4
(Santa Cruz, SC-47527), rabbit polyclonal anti-KCa2.3 (Alomone
labs, APC-025), or mouse monoclonal anti-CD31 (Abcam, ab9498),
each at a dilution of 1:100 in PBS containing 5% BSA] overnight at
4°C in a humidified chamber. After washing with PBS, slides were
incubated with secondary antibodies for 1 h at 37°C. After washing
and mounting, fluorescence images were acquired using a confocal
microscope (Leica TCS SP8). Acceptor photobleaching FRET
measurements were carried out on the TRPV4-CFP+KCa2.3-YFP
samples and the positive and negative controls with the confocal
microscope. FRET efficiency results with the positive control (CFP-
YFP fusion protein with an RNPPVAT-linker) were used as the refer-
ence for ratiometric FRET measurements. CFP was excited by the
458-nm line of an argon ion laser and detected between 465 and
510 nm; YFP was excited at 514 nm and detected between 535 and
590 nm. First, images of the donor and acceptor distributions were
captured. Then, the acceptor dyes were bleached by repetitive scans
with the 514-nm laser at maximal power. After photobleaching, a
donor image was recorded again. The LSM data acquisition software
(Leica TCS SP5 LAS AF version 1.7.0) was used to define regions of
interest and calculate the mean cellular fluorescence intensity in
each channel. Patients with hypertension and normal individuals
were enrolled in our study at the Wuxi People’s Hospital. Vascular
samples from these study participants were dehydrated with sucrose
solution, embedded with optimum cutting temperature compound,
and stored at 80°C.
Stochastic optical reconstruction
microscopy (STROM) measurements
Cells were plated on confocal dishes at ~30% confluence. After 24 h,
the cells were fixed in 3% paraformaldehyde and 0.1% glutaralde-
hyde in PBS, followed by washing with 0.1% sodium borohydride in
PBS. Cells were blocked and permeabilized in blocking buffer (3%
BSA with 0.2% Triton X-100 in PBS), incubated overnight at 4°C with
primary antibody, washed three times, and then incubated for 45 min
at room temperature with the secondary antibody. The primary anti-
bodies used were goat anti-TRPV4 (sc-47527, Santa Cruz) and rabbit
anti-KCa2.3 (APC-025, Alomone). The stains were Alexa Fluor 647
and Alexa Fluor 488 (Invitrogen). Spectrally resolved single-molecule
imaging was performed in standard STROM imaging buffer that
contained 5% (w/v) glucose, 100–200 mM cysteamine, 0.8 mg/ml
glucose oxidase, and 40 lg/ml catalase, in Tris–HCl (pH 7.5 or 8.0).
Approximately 4 ll of imaging buffer was dropped at the center of a
freshly cleaned confocal dish (Xu et al, 2012).
Whole-cell patch clamp
Whole-cell current was measured with an EPC-9 patch clamp ampli-
fier. The pipette solution contained (in mmol/l): CsCl, 20; cesium-
aspartate, 100; MgCl2, 1; ATP, 4; CaCl2, 0.08; 1,2-bis(o-aminophe-
noxy)ethane-N,N,N0,N0-tetraacetate, 10; and Hepes, 10 (pH, 7.2).
Bath solution contained (in mmol/l): NaCl, 150; CsCl, 6; MgCl2, 1;
CaCl2, 1.5; glucose, 10; and Hepes, 10 (pH, 7.4). Cells were clamped
at 0 mV. Whole-cell current density (pA/pF) was recorded in
response to successive voltage pulses of +80 and 80 mV for
100-ms duration and then plotted against time.
Screen and synthesis of JNc-440
JNc-440 was screened as follows: (i) Preparation of receptor mole-
cules: The crystal structural data (PDBNO, 4DX1) of TRPV4 were
downloaded from the PDB database. We used DS to open 4DX1 and
removed water molecules in the system view. With the help of the
Clean Protein tool, hydrogen was added to the protein molecules; the
non-standard name, the incomplete amino acids, and residues with
more than one conformation were corrected. At the same time, the
three-dimensional structure of the KCa2.3 protein was constructed
using the homology modeling method. (ii) Preparation of ligand
molecules: In this experiment, the ligand file used for molecular
docking mainly came from the following four databases: ibs2010-
mar-sc-upd, ibs2010mar-sc1, ibs2010mar-sc2, and TimTec-STOCK-
2010V02. (iii) Definition of the active site of the receptor protein: We
selected 4DX1, expanded Receptor-Ligand Interaction/Define and
Edit Binding Site, in the tool browser and defined 4DX1 as the recep-
tor molecule by clicking Receptor Define. According to the LibDock
docking program, KCa2.3 and 4DX1 were defined as receptors with
which molecular docking was carried out with the databases
ibs2010mar-sc-upd, ibs2010mar-sc1, ibs2010mar-sc2, and TimTec-
STOCK-2010V02. Taking 4DX1 as an example, we selected Ligand in
the system view and Edit in the menu bar; then we clicked Select
and opened its dialog box, choosing the Radius while setting the rest
as Default, and clicked Apply. The AR2 amino acid sequence of the
conserved structure of TRPV4 is (TDEEFREPS)TGKTCLPKALLNL
SNGRNDTIPVLLDIAERTGNMREFINSPFRDIYY (aa 190–236). The
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17C region of KCa2.3 is RKLELTKAEKHVHNFMM (aa 545–561).
Selecting these amino acids, we expanded the Receptor-Ligand Inter-
action/Define and Edit Binding Site in the tool browser and defined a
red ball at the site of conjunction by clicking From Current Selection;
meanwhile, we customized the SBD-Site-Sphere in the system view.
Selecting the SBD-Site-Sphere and right-clicking Attribute of SBD-
Site-Sphere, we changed the radius of the ball to 12. (iv) Using the
Dock Ligands (LibDock) program for molecular docking: After click-
ing Protocols and then Dock Ligands (LibDock) under Receptor-
Ligand Interactions, the parameter setting window of Dock Ligands
(LibDock) appeared. Selecting User Specified from the drop-down
list, the value of Max Hits to save was set to “10”, and other parame-
ters were set to default values. Then, we clicked “run” in the toolbar
to perform molecular docking. (v) Molecular docking results: It was
evident that each docking produced a large number of conforma-
tions, many of which were different conformations of the same mole-
cule, in other words, inconvenient for observation and calculation.
We kept only the conformation with the highest value in LibDockS-
core so that each molecule successful in docking with a protein could
only have one conformation. Using LibDockScore to score and sort,
we compared the conformations of two receptor proteins with scores
> 100. The same molecular with the highest average score was deter-
mined (Rao et al, 2007).
JNc-440 was synthesized as follows: (i) Compound 1 propylene
diamine (30 g, 405 mmol, 1 eq) was dissolved in 150 ml dichloro-
methane and stirred in an ice bath. Di-tert-butyl dicarbonate (16.1 g,
73 mmol, 0.18 eq) was dissolved and diluted in 50 ml dichloro-
methane. The mixture was added slowly to the flask and then stirred
at room temperature for 3 h. When a complete reaction was detected
using thin-layer chromatography (TLC), the reaction solution was
diluted with 50 ml dichloromethane and washed repeatedly with
water, then washed with saturated NaCl solution, and dried over
anhydrous Na2SO4. Compound 2 (19 g, 27%) was obtained after
concentration. (ii) Compound 2 (10 g, 57 mmol, 1 eq) and triethy-
lamine (8.7 g and 86 mmol, 1.5 eq) were dissolved in 100 ml
dichloromethane and stirred in an ice bath. Diphenyl acetyl chloride
(13.1 g, 57 mmol, 1 eq) was dissolved in 30 ml dichloromethane by
slow addition to the flask and stirred at room temperature for 2.5 h.
When a complete reaction was detected using TLC, the crude
product was obtained after concentration. Column chromatography
separation (20:1 dichloromethane/methanol) was conducted to
obtain compound 3 (13.2 g, 63%). (iii) Compound 3 (8 g, 22 mmol,
1 eq) was dissolved in mixed solvent (40 ml, dichloromethane:triflu-
oroacetic acid = 4:1). The mixture was heated in an oil bath at 35°C
for 1 h. When a complete reaction was detected using TLC, ammonia
was used to adjust the pH of the reaction solution to 8–9 until solids
were precipitated. Compound 4 (5.3 g, 90%) was obtained after fil-
tration and drying. (iv) Compound 4 (2 g, 7 mmol, 2 eq) and 4-
quinazoline ketone-2-formic acid ethyl (0.8 g, 3.5 mmol, 1 eq) were
dissolved in 6 ml ethanol and put in a microwave reactor at 100°C
for 45 min. When a complete reaction was detected using TLC, a
white solid was precipitated from the reaction solution after natural
cooling. Compound 5 (JNc-440) (0.7 g, 45%) was obtained after fil-
tering and drying the solid. The structure of JNc-440 was confirmed
with 1H NMR (400 MHz, CDCl3): d: 8.34 (d, J = 7.6 Hz, 1H), 8.20 (s,
1H), 7.76–7.81 (m, 2H), 7.28–7.36 (m, 10H), 6.13 (t, 1H), 4.98 (s,
1H), 3.48 (q, J = 11.2 Hz, 2H), 3.38 (q, 10.2 Hz, 2H), 1.81 (m,
J = 12.4 Hz, 2H). MS (ESI) m/z: 441.3 (M+H)+.
To synthesize biotinylated JNc-440, the following procedures
were performed. (v) Compound 5 (30 mg, 0.068 mmol, 1 eq) was
dissolved in mixed solvent (0.5 ml, acetonitrile:toluene = 1:1) and
stirred, and phosphorus oxychloride (2 drops) was dissolved in
mixed solvent (0.25 ml, acetonitrile:toluene = 1:1) by slow addition
to the flask and stirred at 40°C. DIPEA (3 drops) was dissolved in
mixed solvent (0.25 ml, acetonitrile:toluene = 1:1) by slow addition
to the flask and stirred at 70°C for 3 h. When a complete reaction
was detected using TLC, compound 6 was obtained after rotary
evaporation at 55°C (25 mg, 80.1%). (vi) Compound 6 (25 mg,
0.055 mmol, 1 eq), triethylamine (6.628 mg, 0.066 mmol, 1.2 eq),
and 2-(4-aminophenyl) ethanol (8.986 mg, 0.065 mmol, 1.2 eq)
were dissolved in 1 ml isopropyl alcohol. The mixture was heated
in an oil bath at 45°C for 2 h. When a complete reaction was
detected using TLC, the crude product was obtained after concentra-
tion. Column chromatography separation (20:1 dichloromethane/
methanol) was conducted to obtain compound 7 (20 mg, 65.6%).
(vii) Compound 7 (20 mg, 0.036 mmol, 1 eq) and vitamin H
(10.5 mg, 0.043 mmol, 1.2 eq) were dissolved in 2 ml DMF and
stirred at 45°C. DMAP (0.874 mg, 0.007 mmol, 0.2 eq) was added
to the flask. CDI (6.962 mg, 0.043 mmol, 1.2 eq) was dissolved in
DMF (2 ml) by slow addition to the flask and stirred at 50°C for 3 h.
When a complete reaction was detected using TLC, the crude
product was obtained after concentration. Column chromatography
separation (2:1 petroleum ether:ethyl acetate) was conducted to
obtain compound 8 (biotinylated JNc-440, 6 mg, 21.4%). The struc-
ture of biotinylated JNC-440 was analyzed by 1H NMR (400 MHz,
CDCl3): d: 8.34 (d, J = 7.6 Hz, 1H), 8.20 (s, 1H), 7.76–7.81 (m, 2H),
7.38 (m, 2H), 7.02 (m, 2H), 7.28–7.36 (m, 10H), 6.13 (t, 1H), 4.98
(s, 1H), 4.42 (m, 2H), 3.45 (t, 2H), 3.38 (t, 2H), 3.35 (m, 1H), 2.87
(t, 2H), 2.83 (d, 2H),2.16–2.08 (m, 4H), 2.30 (m, 2H), 1.91 (m, 2H).
1.69–1.62 (m, 4H), 1.26 (m, 2H). MS (ESI) m/z: 784.3 (M+H)+.
Biotinylated JNc-440 pull-down
Primary mesenteric artery ECs were isolated from C57BL/6 mice,
and then cultured cells were treated with biotinylated JNc-440
(10 lM) for 96 h under a 5% CO2 atmosphere at 37°C. Cells were
harvested and lysed with RIPA buffer. For precipitation of biotiny-
lated proteins, 10 ll beads were incubated with cell lysates.
Magnetic streptavidin beads (Thermo Fisher scientific, Waltham,
MA, USA) were washed three times with lysis buffer. Beads were
incubated overnight at 4°C on a rotating platform. After incubation,
beads were washed three times with cell lysis buffer, and bound
proteins were eluted by boiling for 5 min with 50 ll SDS sample
buffer. Samples were separated on an SDS–PAGE gel and transferred
to polyvinylidene fluoride membranes. The membranes were
incubated overnight with primary antibodies (anti-TrpV4 and anti-
KCa2.3) at 4°C. Immunodetection was accomplished using a horse-
radish peroxidase-conjugated secondary antibody (1:3,000) and an
enhanced chemiluminescence detection system (GE Healthcare).
Endothelial cell-specific adeno-associated viruses
To produce EC-specific AAVs, the TRPV4, TRPV4-AR2, and KCa2.3-
17C genes were sub-cloned into pAOV.SYN.3FLAG plasmids to
produce pAOV.SYN.TRPV4.3FLAG, pAOV.SYN.TRPV4-AR2.3FLAG,
and pAOV.SYN.KCa2.3-17C.3FLAG (Neuron Biotech Co., Ltd,
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Shanghai, China), respectively, which had an EC-specific promoter,
flt1. AAV-TRPV4, AAV-TRPV4-AR2, and AAV-KCa2.3-17C were
produced by transfection of AAV-293 cells with pAOV.
SYN.TRPV4.3FLAG, pAOV.SYN.TRPV4-AR2.3FLAG, and pAOV.
SYN.KCa2.3-17C.3FLAG, respectively, with AAV helper plasmid
(pAAV Helper) and AAV Rep/Cap expression plasmid. Viral parti-
cles were purified by iodixanol step-gradient ultracentrifugation.
The genomic titer was 2.5–3.5 × 1012 genomic copies per ml as
determined by quantitative PCR (Wu et al, 2000).
Measurement of intracellular K+ and Ca2+
Intracellular levels of K+ were assessed by determining K+-binding
benzofuran isophthalate (PBFI) fluorescence (Invitrogen P-1267MP)
(Kozoriz et al, 2010). Cells were equilibrated with the cell-permeant
acetoxylmethyl ester of the ion-sensitive dye PBFI (5 lM) for 1 h
and then washed and re-suspended in normal physiological saline
solution (NPSS). Fluorescence was measured using dual excitation
at 340 and 380 nm on an Olympus fluorescence imaging system.
Changes in [K+]i were calculated as the change in the PBFI ratio.
[Ca2+]i in cultured cells was measured with 10 lM Fura-4/AM and
0.02% pluronic F-127 for 1 h in the dark at 37°C in NPSS using the
Leica TSC SP8 confocal microscope.
Plasmids and mutations
For single-site mutation, deletion, or insertion, a PCR of 50 ll
contained 2–10 ng template, 25 ll Prime STAR, and 0.5 ll of each
of the two primer pairs. The PCR cycles were initiated at 95°C for
2 min to denature the template DNA, followed by 19 amplification
cycles. Each cycle consisted of 95°C for 30 s, 56°C for 30 s, and
68°C for 5 min. The PCR cycles ended with an extension step at
68°C for 10 min. The PCR products were treated with five units
DpnI at 37°C for 3 h, and then 10 ll of each PCR was analyzed by
agarose gel electrophoresis. An aliquot of 2 ll of the above PCR
products, the PCR products generated using QuickChangeTM, or
those generated were each transformed into DH5a-competent cells.
The transformed cells were spread on a Luria-Bertani plate contain-
ing antibiotics and incubated at 37°C overnight. The number of
colonies was counted and used as an indirect indication of PCR
amplification efficiency. Four colonies from each plate were grown,
and the plasmid DNA was isolated. The primers were as follows: for
AR1, forward: 50-aagctcctgcacccacggggaagacctg-30, reverse: 50-
caggtcttccccgtgggtgcaggagctt-30; for AR2, forward: 50-cgggagccgtccc
gaggccagaca-30, reverse: 50-tgtctggcctcgggacggctcccg-30; for AR3,
forward: 50-cagagacatctactactttggggagctgccct-30, reverse: 50-aggg
cagctccccaaagtagtagatgtctctg-30; for AR4: forward: 50-gggaggctacttc
tacagggggaacacggtg-30, reverse: 50-caccgtgttccccctgtagaagtagcctcc
c-30; for AR5: forward: 50-ggcgacaggactcggatggcctttcgcc-30, reverse:
50-ggcgaaaggccatccgagtcctgtcgcc-30;for AR6: forward: 50-acctggaga
cagttctcaacaatgatgaggacaccc-30, reverse: 50-gggtgtcctcatcattgttgagaa
ctgtctccaggt-30; for TRPV4-CaMBD: forward: 50-ctaccagtactatggcttc
gagctgaacaagaactcaa-30, reverse: 50-ttgagttcttgttcagctcgaagccatag
tactggtag-30; for 17C: forward: 50-tggtgagctgagtgtcaaccacagctaccaca
a-30, reverse: 50-ttgtggtagctgtggttgacactcagctcacca-30; for a1: forward:
50-catgtgcacaacttcatgatgctaaagaagattgaccatgcc-30, reverse: 50- ggcatg
gtcaatcttctttagcatcatgaagttgtgcacatg-30; for loop: forward: 50-gtcta
taaacatacaaagctgcatgccaaagtcaggaaacac-30, reverse: 50-gtgtttcctgact
ttggcatgcagctttgtatgtttatagac-30; for a2: forward: 50-aaagctgctaaagaa
gattgacatgtatgacttaatcacggagc, reverse: 50-gctccgtgattaagtcatacatgt
caatcttctttagcagcttt-30; for KCa2.3-CaMBD: forward: 50-ctccgtgatta
agtcatacatcatcatgaagttgtgcacatg-30, reverse: 50-catgtgcacaacttcatgat
gatgtatgacttaatcacggag-30; and for KCa2.3-17C-CaMBD: forward: 50-
ccgtgattaagtcatacataaccacagctaccacaaggg-30, reverse: 50-cccttgtggtag
ctgtggttatgtatgacttaatcacgg-30. Sequences were verified by PCR
(Garcia-Elias et al, 2008).
Arterial tension measurement
To measure changes in the isometric tension of arteries, 2-mm rings
of mouse mesenteric artery were mounted in a myograph (Model
610M, Danish Myo Technology, Aarhus, Denmark) and bathed in
oxygenated (95% O2–5% CO2) Krebs solution maintained at 3°C (pH
~7.4). The rings were stretched to an optimal baseline force of 1 mN.
After 60 min of equilibration at baseline tension, 60 mM KCl solu-
tion (the NaCl in Krebs solution was substituted with an equimolar
amount of KCl) was used to confirm the viability of the artery. Arte-
rial rings were contracted with 1 lM phenylephrine. Once a steady-
state tension was obtained, agonists were added to the bath in a
cumulative fashion to obtain concentration–response curves. The
bath solution was modified Krebs solution (Zhang et al, 2014a).
Plasma and EC sample preparation and HPLC-MS/MS analysis
To a 200 ll aliquot of rat plasma, 600 ll acetonitrile was added. After
vortexing the mixture for 30 s and centrifugation at 13,523 g for
8 min, the clear supernatant was transferred into a vial, and 20 ll was
injected for HPLC analysis. Each weighed tissue sample was thawed
and then homogenized in ice-cold physiological saline (250 mg/ml).
Then, 100 ll of tissue homogenate was pipetted and further treated
like the plasma samples. The analysis of JNc-440 was carried out using
a Waters 2695 HPLC system coupled with a Waters Quattro MicroTM
triple quadrupole mass spectrometer (Waters, USA). The separation
was carried out using a Waters XBridge C18 column (50 × 2.1 mm,
3.5 lm). The isocratic mobile phase consisted of acetonitrile–0.1%
formic acid (10:90, v/v) with a flow rate of 0.3 ml/min. The tempera-
ture of the column was maintained at 35°C. The mass spectrometer
was operated in the positive ion detection mode with capillary voltage
3,500 V, desolvation temperature 350°C, and source temperature
100°C. Ion monitoring was performed using the multiple reaction-
monitoring mode in order to measure the following ion transitions:
m/z441?m/z167 was used for quantitation of JNc-440 and m/z497?
m/z192 for the internal standard (Seger et al, 2009).
Statistics
ECs and mice were randomized into different treatment groups for
each experiment, and all mice were used throughout the experi-
ments unless they died. The response of animals to treatment was
quantified by two investigators in a blinded fashion. No statistical
methods were used to predetermine sample size. Sample sizes and
animal numbers were chosen on the basis of previous publications
and experiment types and are indicated in each figure. The results
show the mean  SD. Comparisons among groups were made using
ANOVA or unpaired Student’s t-test, with P < 0.05 as the threshold
for a significant difference.
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The paper explained
Problem
The currently available antihypertensive agents have undesirable adverse
effects due to systemically changing target activity (receptors, channels,
and enzymes). Changes in the vascular resistance of small resistance
arteries have been implicated in the development of hypertension.
However, the critical role of these arteries in the pathogenesis of hyper-
tension has been ignored to date, making them potential targets to
develop new methods to treat hypertension with less adverse effects.
Results
With the goal of effectively treating hypertension and cutting down
on the accompanying adverse effects due to systemic activation of
target, we explored the mechanism of hypertension caused by dysreg-
ulated endothelial TRPV4-KCa2.3 interaction in small resistance arter-
ies; we also identified a possible therapeutic small molecule that
repairs impaired endothelial TRPV4-KCa2.3 interaction but did not
systematically change TRPV4 and KCa2.3 activity.
Impact
Our data highlight the importance of impaired TRPV4-KCa2.3 interac-
tion in the progression of hypertension and provide a novel strategy
for developing new antihypertensive drugs with fewer adverse effects.
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